53 results about "IV Immunoglobulins" patented technology

The present invention describes a method for treating, removing or preventing a bacterial infection, which method comprises administering to a human suffering, suspected of suffering or at risk of suffering from Staphylococcus aureus (S. aureus) infection, a Streptococcus infection, Escherichia coli (E. coli) infection, Pseudomonas aeruginosa (P. aeruginosa) infection, Acinetobacter baumannii (A. baumannii) infection, Enterococcus faecium (E. faecium) infection and / or Clostridium difficile (C. difficile) infection, an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and / or secreted antigen(s) from bacterial cells selected from S. aureus, a Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, and optionally, wherein said affinity purified human polyclonal antibodies are purified (e.g., as made more concentrated as compared to the starting or unpurified material) relative to the same human polyclonal antibodies in the unpurified or non-affinity-purified human blood sample, e.g., intravenous immunoglobulin (IVIG) sample, and / or also optionally, wherein said affinity purified human polyclonal antibodies are specific for the bacterial antigens used in the affinity purification, and / or further optionally wherein the affinity purified human polyclonal antibodies are substantially free of human antibodies that specifically bind to non-bacterial antigens in the human blood sample. Pharmaceutical compositions for treating bacterial infections, comprising an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and / or secreted antigen(s) from S. aureus, Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, are also provided.

A method of providing an immunotherapy treatment to a patient includes determining a level of C1 esterase inhibitor or inhibitor activity in the patient, determining an intravenous immunoglobulin dosing protocol for the patient based on the level of C1 esterase inhibitor or inhibitor activity, and administering the immunotherapy treatment to the patient.

A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titre individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titre individuals; and (d) purifying and / or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titre of specific antibodies is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates. The pathogenic microorganism is preferably smallpox virus or vaccinia virus.

Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and / or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities. While anti-HLA-Ib mAbs can be used to restore anti-tumor activities of CD8+ T cells and Natural killer cells by passive therapy in cancer patients, methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.

The present invention relates to the use of MRI monitoring of ventricular enlargement rate as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen for Alzheimer's patients. Methods for treating Alzheimer's Disease and monitoring therapeutic effectiveness are provided.

The invention provides a method for preparing the intravenous immunoglobulin. The method particularly includes the steps of dissolving component I+II+III or component II+III sediments; separating component I+III-1 or component III-1 sediments; separating component I+III-2 or component III-2 sediments; separating component II sediments; dissolving and filtering the component II sediments; conducting ultrafiltration, dialyzing and concentrating; conducting purification and filtering; conducting ultrafiltration dialysis, concentrating and preparation. By means of the method, steps and step parameters of the traditional process method are improved, specific combinations of the steps and the step parameters can be used for effectively extracting the human immunoglobulin for the intravenous injections from the component I+II+III or component II+III sediments, the technical problems that the human immunoglobulin for the intravenous injections is low in purity, and the content of polymer and the like is slightly high are solved, the pharmacy risk of people is reduced, and the pharmacy safety of people is guaranteed.

The present invention relates to the use of the level of certain cytokines in a patient's blood as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen. Methods for treating Alzheimer's disease and monitoring therapeutic effectiveness are provided.

The invention relates to an immunoglobulin composition suitable for prophylaxis and / or treatment of a viral mediated disease, disorder or condition and to methods of its preparation. In one embodiment, the invention provides a potent intravenous immunoglobulin composition useful for the treatment or prevention of a West Nile virus mediated disease, disorder or condition.

The present invention relates to a method for purifying an immunoglobulin, and more particularly, to a method for purifying an immunoglobulin, which comprises: dissolving immunoglobulin-containing plasma protein fraction I+II+III or fraction II+III; adding caprylate to the solution to cause precipitation; performing dialysis and concentration after removal of the precipitate; performing anion exchange resin and ceramic cation exchange resin purification processes to effectively remove a solvent and detergent added to inactivate viruses; and performing elution while maintaining salt concentration at a constant level to maintain the immunoglobulin polymer content at a low level. According to the method for preparing the intravenous immunoglobulin according to the present invention, a precipitation step of preparing fraction II from fraction I+II+III or fraction II+III as a starting material can be omitted, and problems, including a complicated process and a low yield, which occur in the conventional preparation process employing the polyethylene glycol treatment process, can be solved by use of first sodium caprylate precipitation, anion exchange chromatography and cation exchange chromatography. In addition, when the immunoglobulin purification method according to the present invention is used, the efficiency with which impurities and thrombotic substances are removed can be increased and the immunoglobulin polymer content can be maintained, and thus a stable immunoglobulin with increased quality can be produced.

The invention discloses a method for detecting an activated blood coagulation factor XI in human intravenous immunoglobulin. The method comprises the steps as follows: (1) mixing an IVIG (intravenous immunoglobulin) sample with specially-preprocessed platelet-poor plasma (PPP); (2) adding a thrombin specific fluorogenic substrate with a phospholipid agent into a reaction system; (3) adding an initiation factor for starting a TGT (thrombin generation test), wherein the initiation factor comprises a calcium ion source and the phospholipid agent; (4) obtaining a thrombin generation curve providing parameters by the optimized reaction system; and (5) negatively correlating the peak time of thrombin (TTP) of the detected sample with the FXIa (activated blood coagulation factor XI) level in the sample. The FXIa level in the detected sample can be indirectly obtained by comparing the TTP of the detected sample with that of an FXIa standard sample. The method is suitable for detecting residual micro FXIa in human intravenous immunoglobulin (IVIG) products and is used for extracorporal evaluation of thrombosis risk of related products.

The invention relates to a method for preparing immunoglobulin G by rapidly extracting plasma of a COVID-19 patient in a rehabilitation period, and more particularly, to a method for preparing intravenous injection COVIDI-19 immunoglobulin G by rapidly separating component plasma from whole blood by using a closed multicellular component automatic separation system (MACSS), for example, to prepareintravenous injection superimmunoglobulin. The intravenous immunoglobulin can be used for treating patients infected by novel coronavirus. The method comprises the following steps: separating human peripheral blood into three component layers, namely an erythrocyte layer, a cell concentration layer and a plasma layer, by using a closed multi-cell component automatic separation system, and then carrying out virus inactivation on the obtained plasma to obtain plasma capable of being used for preparing intravenous immunoglobulin G. The invention also relates to a method for preparing an intravenous immunoglobulin G preparation by using the plasma component obtained by the above method. According to the method, the plasma obtaining speed is high, and the antibody titer of the prepared plasmaand intravenous immunoglobulin G is high.

The invention provides a protein protective agent for Pasteur inactivating human intravenous immunoglobulin and an inactivation method of the protein protective agent. A Pasteur inactivation method of human intravenous immunoglobulin comprises the following steps of adding the protein protective agent to a human intravenous immunoglobulin solution before inactivating; adjusting the content of sampled protein to be 40 to 60g / L, and adjusting pH (Potential of Hydrogen) to be 4.7 to 5.3; agitating for 30 minutes; transferring into a water bath under 60+ / - 1 DEG C; maintaining the solution at temperature of 60+ / -0.5 DEG C for 10 hours after the solution temperature reaches 60 DEG C, thus accomplishing the inactivation of human intravenous immunoglobulin, wherein the protein protective agent is saccharose, arginine, glycine and sorbitol which are respective 50 to 70g / L, 20 to 40g / L, 30 to 60g / L and 240 to 260g / L in final content. According to the protein protective agent, simple sorbitol is used as the protective agent, the content of a polymer is decreased from 4.12% to 1.96%, thus the protein can be protected well, and the product quality can be improved.

The invention relates to an integrated scheme for fractionation and purification of plasma products (human albumin, intravenous immunoglobulin (IVIG), clotting factor VIII and clotting factor IX) by sequential chromatography and virus reduction steps. The therapeutically administrable protein IVIG has purity levels exceeding 98%, aggregates and dimers at less than 0.2%, Fc function of >90% and anti-complementary activity of less than 0.5 CH50 per mg of Ig. The distribution of IgG isomers is comparable to the ranges seen in normal plasma. Human albumin for therapeutic use, purified by this integrated scheme has an electrophoretic purity of close to 100%, with monomers exceeding 98%. The levels of aluminium and pre-kallikrein activator are below the detection limit for the respective tests. The Factor IX preparations have a specific activity of ≧200 IU / mg. The impurity levels of Factor-II, Factor VII, Factor X are at least 10-fold lesser (≦0.5% instead of 5%) and the heparin impurity of ≦0.01 IU (against 0.5 IU limit for this impurity) is 50-fold lesser the specified pharmacopoeial limits.The purification carried out by an all-chromatography scheme, avoids the use of ethanol precipitation in the entire manufacturing process of the said four plasma products. The invention describes an integrated process for purifying four different proteins from human plasma to high therapeutic grade purity levels, with a potential to purify more therapeutic proteins from a given plasma sample by incorporating additional chromatography steps in the sequence.

The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.

The invention relates to a method for rapidly extracting plasma of a COVED-19 patient in a rehabilitation period by an automatic separation system. The method comprises the following steps of: separating peripheral blood taken from a human body into three component layers, namely an erythrocyte layer, a cell concentration layer and a plasma layer, by using a closed multi-cell component automatic separation system, performing virus inactivation on the obtained plasma, and optionally cryopreserving the plasma to obtain the plasma which can be used for preparing intravenous immunoglobulin G. Theinvention also comprises a method for preparing an intravenous immunoglobulin G preparation. The method comprises the following steps: obtaining a plasma component by the method, precipitating the plasma by a low-temperature ethanol method to obtain components I + II + III, separating a component II from a component I + III, respectively preparing an immunoglobulin G semi-finished product 1 and animmunoglobulin G semi-finished product 2, performing sterilization and virus inactivation to obtain an immunoglobulin G stock solution. and further preparing the intravenous immunoglobulin G preparation for intravenous injection. The method provided by the invention achieves excellent technical effects as described in the specification.

The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.

The present invention relates to the use of the level of certain cytokines in a patient's blood as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen. Methods for treating Alzheimer's disease and monitoring therapeutic effectiveness are provided.

The present subject matter is directed to a method of manufacturing purified IVIG from Fraction III of plasma, comprising re-constituting a Fraction III paste in a buffer; adjusting the pH and temperature; adding ethanol and then gradually lowering the temperature; centrifuging and filtering the supernatant; ultra-filtrating to remove alcohol; undergoing weak anion exchange chromatography; ultra-filtrating to reach a desired protein concentration; aseptic filtrating; nano filtrating for virus removal; and incubating at low pH for virus inactivation to obtain a resulting Fraction III suspensioncomprising purified IVIG. The present subject matter is directed to IVIG having 14 newly-found proteins, namely KH 26, KH 27, KH 28, KH 29, KH 30, KH 31, KH 32, KH 33, KH 39, KH 40, KH 41, KH 42, KH43, and KH 44 for both liquid and lyophilized form.

Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and / or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use.

The invention provides a production process for intravenous immunoglobulin, which comprises separating the components I+II+III / II+III from healthy human plasma; Through the following chromatography: anion chromatography A, anion chromatography B, affinity chromatography C; after chromatography, the washing solution is prepared by ultrafiltration, concentration or dilution, and then filtered through a nano-membrane, incubated at a low pH value, and incubated After release, the solution is mixed, prepared and sterilized to obtain immunoglobulin for intravenous injection. The production process provided by the present invention can obtain IgG products with high yield and purity, and more importantly, the anti-A, anti-B indexes and ACA indexes of the obtained products are all greatly reduced, which meets the requirements of "Chinese Pharmacopoeia" well , and the osmolarity of the sample also meets the requirements very well.

The invention provides a protein protective agent for Pasteur inactivating human intravenous immunoglobulin and an inactivation method of the protein protective agent. A Pasteur inactivation method of human intravenous immunoglobulin comprises the following steps of adding the protein protective agent to a human intravenous immunoglobulin solution before inactivating; adjusting the content of sampled protein to be 40 to 60g / L, and adjusting pH (Potential of Hydrogen) to be 4.7 to 5.3; agitating for 30 minutes; transferring into a water bath under 60+ / - 1 DEG C; maintaining the solution at temperature of 60+ / -0.5 DEG C for 10 hours after the solution temperature reaches 60 DEG C, thus accomplishing the inactivation of human intravenous immunoglobulin, wherein the protein protective agent is saccharose, arginine, glycine and sorbitol which are respective 50 to 70g / L, 20 to 40g / L, 30 to 60g / L and 240 to 260g / L in final content. According to the protein protective agent, simple sorbitol is used as the protective agent, the content of a polymer is decreased from 4.12% to 1.96%, thus the protein can be protected well, and the product quality can be improved.

The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII / FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory Fcγ R; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.

The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII / FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory FcγR; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.

The invention belongs to the technical field of Kawasaki disease medical equipment, and particularly discloses a system and device for predicting the resistance of child suffering Kawasaki disease after first injection of intravenous immunoglobulin, the prediction system comprises: a data acquisition module which is used for acquiring baseline data, image data and laboratory data of a sample before first IVIG treatment; a data processing module which is used for receiving and processing the data information acquired by the data acquisition module and acquiring variable parameters; a risk factor acquisition module which is used for receiving the variable parameters and screening to obtain IVIG resistance risk factors; and the prediction module which is used for bringing the IVIG resistance risk factors into a machine learning model and establishing a prediction model. According to the technical scheme, through cooperation of all the modules, collection and screening of sample information are achieved, and whether a child patient has first dose IVIG resistance or not is predicted according to the acquired information.

The invention relates to an application of intravenous immunoglobulins (IVIg) in preparing a medicament for treating autoimmune diseases of a peripheral nervous system, the autoimmune diseases are related ganglioside GM1 antibody diseases, and the IVIg is used for treating the related ganglioside GM1 antibody diseases by inhibiting cholera toxin and galectin from being combined into ganglioside GM1. The advantages are as follows: the research finds that the IVIg can not inhibit the combination of the GM1 antibody with the antigen thereof and the GM1 antibody titer is not reduced, the inhibition of the IVIg on the combination of the cholera toxin and galectin into the GM1 can be displayed; and put forward in a first time, galactosyl / non-galactosyl immune globulin with correction rate in the IVIg are mutually acted on a macrophage receptor, so that the inflammation functions of autoimmune disease of macrophage and a peripheral nervous system can be reduced.

The present subject matter is directed to a process of cloning and purifying recombinant intravenous immunoglobulin (IVIG), comprising cloning a target gene of human immunoglobulin; in vitro screeningof a yeast cell expressing the target gene of human immunoglobulin to create a yeast cell line; fermenting the yeast cell line and collecting a resulting culture medium; filtering the culture medium;undergoing weak anion exchange chromatography to collect a flow-through solution; ultra-filtrating the flow-through solution to reach a desired protein concentration; aseptic filtrating the flow-through solution; nano-filtrating the flow-through solution for virus removal; and filling and incubating the flow-through solution at low pH for virus inactivation to obtain a purified recombinant IVIG.The present subject matter is directed to purified recombinant IVIG having five newly-found proteins, namely KH 33, KH 34, KH 35, KH 36, and KH 37 for both liquid and lyophilized forms.

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, Treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (WIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a T cell mediated pediatric vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or Juvenile Idiopathic Arthritis; a neoplastic hematological disorder, or a leukemia.